Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status

Molecular Nutrition and Food Research

Volumn 61, Issue 1, 2017, Pages

  Tomás Barberán, Francisco A ^a   González Sarrías, Antonio ^a   García Villalba, Rocío ^a   Núñez Sánchez, María A ^a   Selma, María V ^a   García Conesa, María T ^a   Espín, Juan Carlos ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

Author keywords

Ellagic acid; Ellagitannins; Gut microbiota metabolites; Interindividual variability; Urolithins

Indexed keywords

3,8-DIHYDROXY-6H-DIBENZO(B,D)PYRAN-6-ONE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; COUMARIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; TANNIN;

ANIMAL; DRUG EFFECTS; DYSBIOSIS; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE FLORA; LIPID METABOLISM; MASS SPECTROMETRY; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HEALTH STATUS; HUMANS; HYDROLYZABLE TANNINS; LIPID METABOLISM; MASS SPECTROMETRY;

EID: 84977563497     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500901     Document Type: Review

References (147)

1. Larrosa, M., García-Conesa, M. T., Espín, J. C., Tomás-Barberán, F. A., Ellagitannins, ellagic acid and vascular health. Mol. Asp. Med. 2010, 31, 513–539.
2. García-Muñoz, C., Vaillant, F., Metabolic fate of ellagitannins: implications for health, and research perspectives for innovative functional foods. Crit. Rev. Food Sci. Nutr. 2014, 54, 1584–1598.
3. Lipinski, C. A., Lombardo, F., Dominy, B. V., Feeney, P. J., Experimental and computational approaches to estimate solubility and permeation in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3–25.
4. Cerdá, B., Espín, J. C., Parra, S., Martínez, P. et al., The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivates by the colonic microflora of healthy humans. Eur. J. Nutr. 2004, 43, 205–220.
5. González-Barrio, R., Truchado, P., Ito, H., Espín, J. C. et al., UV and MS identification of urolithins and nasutins, the bioavailable metabolites of ellagitannins and ellagic acid in different mammals. J. Agric. Food Chem. 2011, 59, 1152–1162.
6. Lederer, E., Chemistry and biochemistry of some mammalian secretions and excretions. J. Chem. Soc. 1949, 2115–2125.
7. Pope, G. S., Isolation of two benzocoumarins from ‘Clover Stone’, a type of renal calculus found in sheep. Biochem. J. 1964, 93, 744–747.
8. Mao, Z., Sum, W., Fu, L., Luo, H. et al., Natural dibenzo-α-pyranones and their bioactivities. Molecules 2014, 19, 5088–5108.
9. Garadz, Y. L., Garadz, M. M., Natural dibezo[b,d]pyran-6-ones: structural diversity, and biological activity. Chem. Nat. Compd. 2016, 52, 1–18.
10. Doyle, B., Griffiths, L. A., The metabolism of ellagic acid in the rat. Xenobiotica 1980, 10, 247–256.
11. Cerdá, B., Llorach, R., Cerón, J. J., Espín, J. C. et al., Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur. J. Nutr. 2003, 42, 18–28.
12. Cerdá, B., Tomás-Barberán, F. A., Espín, J. C. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J. Agric. Food Chem. 2005, 53, 227–235.
13. Espín, J. C., Larrosa, M., García-Conesa, M. T., Tomás-Barberán, F., Biological significance of urolithins, the gut microbial ellagic acid-deriver metabolites: the evidence so far. Evid. Based Complement. Alternat. Med. 2013, 2013, 270418.
14. González-Sarrías, A., García-Villalba, R., Núñez-Sánchez, M. A., Tomé-Carneiro, J. et al., Identifying the limits for ellagic acid bioavailability: a crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts. J. Funct. Foods 2015, 19, 225–235.
15. Ludwing, I. A., Mena, P., Calani, L., Borges, G. et al., New insights into the bioavailability of red raspberry anthocyanins and ellagitannins. Free Radic. Biol. Med. 2015, 89, 758–769.
16. Cerdá, B., Soto, C., Albadalejo, M. D., Martínez, P. et al., Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial. Eur. J. Nutr. 2006, 60, 245–253.
17. Pfundstein, B., Haubner, R., Würtele, G., Gehres, N. et al., Pilot walnut intervention study of urolithin bioavailability in human volunteers. J. Agric. Food Chem. 2014, 62, 10264–10273.
18. Yang, J., Lee, R., Henning, S. M., Thames, G. et al., Soy protein isolate does not affect ellagitannin bioavailability and urolithin formation when mixed with pomegranate juice in humans. Food Chem. 2016, 194, 1300–1303.
19. Li, Z., Henning, S. M., Lee, R. P., Lu, Q. Y. et al., Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 2015, 6, 2487–2495.
20. Nuñez-Sánchez, M. A., García-Villalba, R., Monedero-Saiz, T., García-Talavera, N. V. et al., Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol. Nutr. Food Res. 2014, 58, 1199–1211.
21. Seeram, N. P., Zhang, Y., McKeever, R., Henning, S. M. et al., Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J. Med. Food 2008, 11, 390–394.
22. Mosele, J. I., Gosalbes, M. J., Maciá, A., Rubió, L. et al., Effect of daily intake of pomegranate juice on fecal microbiota and feces metabolites from healthy volunteers. Mol. Nutr. Food Res. 2015, 59, 1942–1953.
23. González-Barrio, R., Borges, G., Mullen, W., Crozier, A., Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. J. Agric. Food Chem. 2010, 58, 3933–3939.
24. Espín, J. C., González-Barrio, R., Cerdá, B., López-Bote, C. et al., Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J. Agric. Food Chem. 2007, 55, 10476–10485.
25. Cerdá, B., Periago, P., Espín, J. C., Tomás-Barberán, F. A., Identification of urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds. J. Agric. Food Chem. 2005, 53, 5571–5576.
26. Romo-Vaquero, M., García-Villalba, R., González-Sarrías, A., Beltrán, D. et al., Interindividual variability in the human metabolism of ellagic acid: contribution of Gordonibacter to urolithin production. J. Funct. Foods 2015, 17, 785–791.
27. García-Villalba, R., Beltrán, D., Espín, J. C., Selma, M. V. et al., Time course production of urolithins from ellagic acid by human gut microbiota. J. Agric. Food Chem. 2013, 61, 8797–8806.
28. Kosmala, M., Zdunczyk, Z., Juskiewicz, J., Jurgonski, A. et al., Chemical composition of defatted strawberry and raspberry seeds and the effect of these dietary ingredients on polyphenol metabolites, intestinal function, and selected serum parameters in rats. J. Agric. Food Chem. 2015, 63, 2989–2996.
29. Seeram, N. P., Aronson, W. J., Zhang, Y., Henning, S. M. et al., Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J. Agric. Food Chem. 2007, 55, 7732–7737.
30. Natella, F., Leoni, G., Maldini, M., Natarelli, L. et al., Absorption, metabolism, and effects at transcriptome level of a standardized french oak wood extract, Robuvit, in healthy volunteers: pilot study. J. Agric. Food Chem. 2014, 62, 443–453.
31. García-Muñoz, C., Hernández, L., Pérez, A., Vaillant, F., Diversity of urinary excretion patterns of main ellagitannins’ colonic metabolites after ingestion of tropical highland blackberry (Rubus adenotrichus) juice. Food Res. Inter. 2014, 55, 161–169.
32. Tulipani, S., Urpi-Sarda, M., García-Villalba, R., Rabassa, M. et al., Urolithins are the main urinary microbial-derived phenolic metabolites discriminating a moderate consumption of nuts in free-living subjects with diagnosed metabolic syndrome. J. Agric. Food Chem. 2012, 60, 8930–8940.
33. González-Barrio, R., Edwards, C. A., Crozier, A., Colonic catabolism of ellagitannins, ellagic acid, and raspberry anthocyanins: in vivo and in vitro studies. Drug Metab. Dispos. 2011, 39, 1680–1688.
34. Azorín-Ortuño, M., Urbán, C., Cerón, J. J., Tecles, F. et al., Safety evaluation of an oak-flavored milk powder containing ellagitannins upon oral administration in the rat. J. Agric. Food Chem. 2008, 56, 2857–2865.
35. Truchado, P., Larrosa, M., García-Conesa, M. T., Cerdá, B. et al., Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. J. Agric. Food. Chem. 2012, 60, 5749–5754.
36. Fotschki, B., Milala, J., Jurgonski, A., Karlinska, E. et al., Strawberry ellagitannins thwarted the positive effects of dietary fructooligosaccharides in rat cecum. J. Agric. Food Chem. 2014, 62, 5871–5880.
37. Ito, H., Iguchi, A., Hatano, T., Identification of urinary and intestinal bacterial metabolites of ellagitannin geraniin in rats. J. Agric. Food Chem. 2008, 56, 393–400.
38. Seeram, N. P., Henning, S. M., Zhang, Y., Suchard, M. et al., Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J. Nutr. 2006, 136, 2481–2485.
39. Haddad, E. H., Gaban-Chong, N., Oda, K., Sabaté, J. Effect of a walnut meal on postprandial oxidative stress and antioxidants in healthy individuals. Nutr. J. 2014, 13, 1–9.
40. García-Villalba, R., Espín, J. C., Tomás-Barberán, F. A., Chromatographic and spectroscopic characterization of urolithins for their determination in biological samples after the intake of foods containing ellagitannins and ellagic acid. J. Chromatogr. A. 2016, 1428, 162–175.
41. Freedland, S. J., Carducci, M., Kroeger, N., Partin, A. et al., A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men prostate cancer before radical prostatectomy. Cancer Prev. Res. 2013, 6, 1120–1127.
42. Braune, A., Blaut, M., Intestinal bacterium Eubacterium cellulosolvens deglycosylates flavonoid C- and O-glycosides. Appl. Env. Microbiol. 2012, 78, 8151–8153.
43. Aguilar-Zarate, P., Cruz-Hernandez, M. A., Montañez, J. C., Belmars-Cerda, R. E., Aguilar, C. N., Bacterial tannases: Production, properties and applications. Rev. Mex. Ing. Quim. 2014, 13, 63–74.
44. De Felipe, F. L., de las Rivas, B., Muñoz, R., Bioactive compounds produced by gut microbial tannase: implications for colorectal cancer development. Front. Microbiol. 2014, 5, 1–4.
45. Selma, M. V., Espín, J. C., Tomás-Barberán, F. A., Interaction between phenolics and gut microbiota: role in human health. J. Agric. Food Chem. 2009, 57, 6485–6501.
46. Selma, M. V, Beltrán, D., García-Villalba, R., Espín, J. C. et al., Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. 2014, 5, 1779–1784.
47. Selma, M. V., Tomas-Barberan, F. A., Beltran, D., Garcia-Villalba, R. et al., Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. Int. J. Syst. Evol. Microbiol. 2014, 64, 2346–2352.
48. Wang, X., Hur, H., Lee, J. H., Kim, K. T. et al., Enantioselective synthesis of S-Equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium Appl. Environ. Microbiol. 2005, 71, 214–219.
49. Jin, J. S., Kitahara, M., Sakamoto, M., Hattori, M. et al., Slackia equolifaciens sp. nov., a human intestinal bacterium capable of producing equol. Int. J. Syst. Evol. Microbiol. 2010, 60, 1721–1724.
50. Matthies, A., Blaut, M., Braune, A., Isolation of a human intestinal bacterium capable of daidzein and genistein conversion. Appl. Environ. Microbiol. 2009, 75, 1740–1744.
51. Possemiers, S., Bolca, S., Grootaert, C., Heyerick, A. et al., The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J. Nutr. 2006, 136, 1862–1867.
52. Clavel, T., Henderson, G., Alpert, C., Philippe, C. et al., Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and enterolactone in humans. Appl. Environ. Microbiol. 2005, 71, 6077–6085.
53. Tomás-Barberán, F., García-Villalba, R., Quartieri, A., Raimondi, S. et al., In vitro transformation of chlorogenic acid by human gut microbiota. Mol. Nutr. Food Res. 2014, 58, 1122–1131.
54. Tomás-Barberán, F. A., García-Villalba, R., González-Sarrías, A., Selma, M. V. et al., Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J. Agric. Food Chem. 2014, 62, 6535–6538.
55. Bode, L. M., Bunzel, D., Huch, M., Cho, G. et al., In vivo and in vitro metabolism of trans-resveratrol by human gut. Am. J. Clin. Nutr. 2013, 97, 295–309.
56. Maruo, T., Sakamoto, M., Ito, C., Toda, T. et al., Adlercreutzia equolifaciens gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces, and emended description of the genus Eggerthella. Int. J. Syst. Evol. Microbiol. 2008, 58, 1221–1227.
57. Wang, Y., Qiu, Z., Zhou, B., Liu, C. et al., In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. Toxicol. In Vitro. 2015, 29, 1107–1115.
58. Dueñas, M., Muñoz-Gonzalez, I., Cueva, C., Jimenez-Giron, A. et al., A survey of modulation of gut microbiota by dietary polyphenols. Biomed. Res. Int. 2015, 2015, 850902.
59. Bialonska, D., Ramnani, P., Kasimsetty, S. G., Muntha, K. R. et al., The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int. J. Food Microbiol. 2010, 140, 175–182.
60. Larrosa, M., González-Sarrías, A., Yáñez-Gascón, M. J., Selma, M. V. et al., Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J. Nutr. Biochem. 2010, 21, 717–725.
61. Anhe, F. F., Roy, D., Pilon, G., Dudonné, S. et al., A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp- population in the gut microbiota of mice. Gut. 2015, 64, 872–883.
62. García-Villalba, R., Espín, J. C., Aaby, K., Alasalvar, C. et al., Validated method for the characterization and quantification of extractable and non-extractable ellagitannins after acid hydrolysis in pomegranate fruits, juices and extracts. J. Agric. Food Chem. 2015, 63, 6555–6566.
63. Giménez-Bastida, J. A., Truchado, P., Larrosa, M., Espín, J. C. et al., Urolithins, ellagitannin metabolites produced by colon microbiota, inhibit Quorum Sensing in Yersinia enterocolitica: phenotypic response and associated molecular changes. Food Chem. 2012, 132, 1465–1474.
64. Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D. et al., Enterotypes of the human gut microbiome. Nature. 2011, 473, 174–180.
65. Cani, P. D., Everand, A., Talking microbes: when gut bacteria interacts with diet and host organs. Mol. Nutr. Food Res. 2016, 60, 58–66.
66. González-Sarrías, A., Giménez-Bastida, J. A., García-Conesa, M. T., Gómez-Sánchez, M. B. et al., Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol. Nutr. Food Res. 2010, 54, 311–322.
67. Puupponen-Pimiä, R., Seppänen-Laakso, T., Kankainen, M., Maukonen, J. et al., Effects of ellagitannin-rich berries on blood lipids, gut microbiota, and urolithin production in human subjects with symptoms of metabolic syndrome. Mol. Nutr. Food Res. 2013, 57, 2258–2263.
68. Selma, M. V., Romo-Vaquero, M., García-Villalba, R., González-Sarrías, A. et al., The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism. Food Funct. 2015. doi: 10.1039/C5FO01100K.
69. Mora-Cubillos, X., Tulipani, S., Garcia-Aloy, M., Bulló, M. et al., Plasma metabolomic biomarkers of mixed nuts exposure inversely correlate with severity of metabolic syndrome. Mol. Nutr. Food Res. 2015, 59, 2480–2490.
70. Bookheimer, S. Y., Renner, B. A., Ekstrom, A., Li, Z.et al., Pomegranate juice augments memory and fMRI activity in middle-aged and older adults with mild memory complaints. Evid. Based Complement. Alternat. Med. 2013, 2013, 946298.
71. González-Barrio, R., Truchado, P., García-Villalba, R., Hervás, G. et al., Metabolism of oak leaf ellagitannins and urolithin production in beef cattle. J. Agric. Food Chem. 2012, 60, 3068–3077.
72. Gasperotti, M., Passamonti, S., Tramer, F., Masuero, D. et al., Fate of microbial metabolites of dietary polyphenols in rats: is the brain their target destination? ACS Chem. Neurosci. 2015, 6, 1341–1352.
73. Espín, J. C., García-Conesa, M. T., Tomás-Barberán, F. A., Nutraceuticals: facts and fiction. Phytochemistry. 2007, 68, 2896–3008.
74. Sala, R., Mena, P., Savi, M., Brighenti, F. et al., Urolithins at physiological concentrations affect the levels of pro-inflammatory cytokines and growth factor in cultured cardiac cells in hyperglucidic conditions. J. Funct. Foods. 2015, 15, 97–105.
75. Giorgio, C., Mena, P., Del Rio, D., Brighenti, F. et al., The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol. Nutr. Food Res. 2015, 59, 2155–2167.
76. Mele, L., Mena, P., Piomontese, A., Marino, A. et al., Antioatherogenic effects of ellagic acid and urolithins in vitro. Arch. Biochem. Biophys. 2016. doi:10.1016/j.abb.2016.02.017.
77. González-Sarrías, A., Núñez-Sánchez, M. A., Tomé-Carneiro, J., Tomás-Barberán, F. A. et al., Comprehensive characterization of the effects of ellagic acid and urolithins on colorectal cancer and key associated molecular hallmarks: microRNA-cell specific induction of CDKN1A (p21) as a common mechanism involved. Mol. Nutr. Food Res. 2015. doi: 10.1002/mnfr.201500780.
78. González-Sarrías, A., Giménez-Bastida, J. A., Núñez-Sánchez, M. A., Larrosa, M. et al., Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. Eur. J. Nutr. 2014, 53, 853–864.
79. Cho, H., Jung, H., Lee, H., Yi, H. C. et al., Chemopreventive activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon cancer cells. Food Funct. 2015, 6, 1675–1683.
80. Sánchez-González, C., Ciudad, C. J., Izquierdo-Pulido, M., Noé, V., Urolithin A causes p21 up-regulation in prostate cancer cells. Eur. J. Nutr. 2015. doi: 10.1007/s00394-015-0924-z.
81. González-Sarrías, A., Azorín-Ortuño, M., Yáñez-Gascón, M. J., Tomás-Barberán, F. A. et al., Dissimilar in vitro and in vivo effects of ellagic acid and its microbiota-derived metabolites, urolithins, on the cytocrhrome P450 1A1. J. Agric. Food Chem. 2009, 57, 5623–5632.
82. Giménez-Bastida, J. A., González-Sarrías, A., Larrosa, M., Tomás-Barberán, F. et al., Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells. Mol. Nutr. Food Res. 2012, 56, 784–796.
83. Piwowarski, J. P., Granica, S., Kiss, A. K., Influence of gut microbiota-derived ellagitannins′ metabolites urolithins on pro-inflammatory activities of human neutrophils. Planta Med. 2014, 80, 887–895.
84. Piwowarski, J. P., Granica, S., Zwierzynska, M., Stefanska, J. et al., Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials. J. Ethnopharmacol. 2014, 155, 801–809.
85. González-Sarrías, A., Larrosa, M., Tomás-Barberán, F. A., Dolara, P. et al. C., NF-kappaB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts. Br. J. Nutr. 2010, 104, 503–512.
86. Giménez-Bastida, J. A., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F. et al., Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. J. Agric. Food Chem. 2012, 60, 8866–8876.
87. Ishimoto, H., Shibata, M., Myojin, Y., Ito, H. et al., In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg. Med. Chem. Lett. 2011, 21, 5901–5904.
88. Gallardo, C., Jiménez, L., García-Conesa, M. T., Hydroxycinnamic acid composition and in vitro antioxidant activity of selected grain fractions. Food Chem. 2006, 99, 455–463.
89. Bialonska, D., Kasimsetty, S. G., Khan, S. I., Ferreira, D., Urolithins, intestinal microbial metabolites of pomegranate-ellagitannins, exhibit potent antioxidant activity in a cell-based assay. J. Agric. Food Chem. 2009, 57, 10181–10186.
90. Qiu, Z., Zhou, B., Jin, L., Yu, H. et al., In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem. Toxicol. 2013, 59, 428–437.
91. Olennikov, D. N., Kashchenko, N. I., Chirikova, N. K., In vitro bioaccessibility, human gut microbiota metabolites and hepatoprotective potential of chebulic ellagitannins: a case of Padma Hepaten (®) formulation. Nutrients. 2015, 7, 8456–8477.
92. Ito, M., Metabolites of the ellagitannin geraniin and their antioxidant activities. Planta Med. 2011, 77, 1110–1115.
93. Medjakovic, S., Jungbauer, A., Pomegranate: a fruit that ameliorates metabolic syndrome. Food Funct. 2013, 4, 19–39.
94. Rosenblat, M., Volkova, N., Borochov-Neori, H., Judeinstein, S. et al., Anti-atherogenic properties of date vs. pomegranate polyphenols: the benefits of the combination. Food Funct. 2015, 6, 1496–1509.
95. Kang, I., Kim, Y. E., Tomás-Barberán, F. A., Espín, J. C. et al., Urolithin A, C and D, but not iso-Urolithin A and Urolithin B, attenuate triglyceride accumulation in primary cultures of human adipocytes. Mol. Nutr. Food Res. 2016. doi:10.1002/mnfr.201500796.
96. Larrosa, M., González-Sarrías, A., García-Conesa, M. T., Tomás-Barberán, F. A. et al., Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J. Agric. Food Chem. 2006, 54, 1611–1620.
97. Dellafiora, L., Mena, P., Cozzini, P., Brighenti, F. et al., Modelling the posible bioactivity of ellagitannin-derived metabolites. In silico tools to evaluate their potential xenoestrogenic behavior. Food Funct. 2013, 4, 1442–1451.
98. Verzelloni, E., Pellacani, C., Tagliazucchi, D., Tagliaferri, S. et al., Antiglycative and neuroprotective activity of colon-derived polyphenol catabolites. Mol. Nutr. Food Res. 2011, 55, 35–43.
99. Ito, H., Li, P., Koreishi, M., Nagatomo, A. et al., Ellagitannin oligomers and a neolignan from pomegranate arils and their inhibitory effects on the formation of advanced glycation end products. Food Chem. 2014, 152, 323–330.
100. Liu, W., Ma, H., Frost, L., Yuan, T. et al., Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging carbonyl species. Food Funct. 2014, 5, 2996–3004.
101. Yuan, T., Ma, H., Liu, W., Niesen, D. B., Pomegranate's neuroprotective effects against Alzheimer's disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites. ACS Chem. Neurosci. 2016, 7, 26–33.
102. Subash, S., Essa, M. M., Al-Asmi, A., Al-Adawi, S. et al., Pomegranate from Oman alleviates the brain oxidative damage in transgenic mouse model of Alzheimer's disease. J. Tradit. Complement. Med. 2014, 4, 232–238.
103. Subash, S., Braidy, N., Essa, M. M., Zayana, A. B. et al., Long-term (15 mo) dietary supplementation with pomegranates from Oman attenuates cognitive and behavioral deficits in a transgenic mice model of Alzheimer's disease. Nutrition. 2015, 31, 223–229.
104. Dell'agli, M., Galli, G. V., Bulgari, M., Basilico, N. et al., Ellagitannins of the fruit rind of pomegranate (Punica granatum) antagonize in vitro the host inflammatory response mechanisms involved in the onset of malaria. Malar. J. 2010, 9, 208.
105. Jeong, S. J., Kim, N. Y., Kim, D. H., Kang, T. H., et al., Hyaluronidase inhibitory active 6H-dibenzo[b,d]pyran-6-ones from the feces of Trogopterus xanthipes. Planta Med. 2000, 66, 76–77.
106. Furlanetto, V., Zagotto, G., Pasquale, R., Moro, S. et al., Ellagic acid and polyhydroxilated urolithins are potent catalytic inhibitors of human topoisomerase II: an in vitro study. J. Agric. Food Chem. 2012, 60, 9162–9170.
107. Gulcan, H. O., Unlu, S., Esiringu, I., Ercetin, T. et al., Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[o]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorg. Med. Chem. 2014, 22, 5141–5154.
108. Núñez-Sánchez, M. A., Dávalos, A., González-Sarrías, A., Casas-Agustench, P. et al., MicroRNAs expression in normal and malignant colon tissues as biomarkers of colorectal cancer in response to pomegranate extracts consumption: critical issues to discern between modulatory effects and potential artefacts. Mol. Nutr. Food Res. 2015, 59, 1973–1986.
109. Lotito, S. B., Frei, B., Relevance of apple polyphenols as antioxidants in human plasma: contrasting in vitro and in vivo effects. Free Radic. Biol. Med. 2004, 36, 201–211.
110. Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F. A. et al., Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19, 6064–6093.
111. Willenberg, I., Meschede, A. K., Gueler, F., Jang, M. S. et al., Food polyphenosl fail to cause biologically relevant reduction of COX-2 activity. PLoS One. 2015, 10, e0139147.
112. Frankenfeld, C. L., Atkinson, C., Thomas, W. K., Gonzalez, A. et al., High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br. J. Nutr. 2005, 94, 873–876.
113. Frankenfeld, C. L., Atkinson, C., Wähälä, K., Lampe, J. W., Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein. Eur. J. Clin. Nutr. 2014, 68, 526–530.
114. Atkinson, C., Newton, K. M., Yong, M., Stanczyk, F. Z. et al., Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States. Metabolism. 2012, 61, 1678–1682.
115. Hazim, S., Curtis, P. J., Schär, M. Y., Ostertag, L. M. et al., Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. Am. J. Clin. Nutr. 2016. doi: 10.3945/ajcn.115.125690.
116. Jackman, K. A., Woodman, O. L., Chrissobolis, S., Sobey, C. G., Vasorelaxant and antioxidant activity of the isoflavone metabolite equol in carotid and cerebral arteries. Brain Res. 2007, 1141, 99–107.
117. Aviram, M., Dornfeld, L., Rosenblat, M., Volkova, N. et al., Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 2000, 71, 1062–1076.
118. Esmaillzadeh, A., Tahbaz, F., Gaieni, I., Alavi-Majd, H., et al., Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. J. Med. Food 2004, 7, 305–308.
119. Matthaiou, C. M., Goutzourelas, N., Stagos, D., Sarafoglou, E. et al., Pomegranate juice consumption increases GSH levels and reduces lipid and protein oxidation in human blood. Food Chem. Toxicol. 2014, 73, 1–6.
120. Shema-Didi, L., Sela, S., Ore, L., Shapiro, G. et al., One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial. Free Radic. Biol. Med. 2012, 53, 297–304.
121. Sahebkar, A., Simental-Mendía, L. E., Giorgini, P., Ferri, C. et al., Lipid profile changes after pomegranate consumption: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2016. doi: 10.1016/j.phymed.2015.Shaebkar 2016.
122. Cerdá, B., Cerón, J. J., Tomás-Barberán, F. A., Espín, J. C., Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J. Agric. Food Chem. 2003, 51, 3493–3501.
123. Gasperotti, M., Masuero, D., Gella, G., Mattivi, F. et al., Development of a targeted method for twenty-three metabolites related to polyphenol gut microbial metabolism in biological samples, using SPE and UHPLC–ESI-MS/MS Talanta. 2014, 128, 221–230.
124. van der Hooft, J. J. J., de Vos, R. C. H., Mihaleva, V., Bino, R. J. et al., Structural elucidation and quantification of phenolic conjugates present in human urine after tea intake. Anal. Chem. 2012, 84, 7263–7271.
125. Mertens-Talcott, S. U., Jilma-Stohlawetz, P., Rios, J., Hingorani, L., Derendorf, H., Absorption, metabolism, and antioxidant effect of pomegranate (Punica granatum L.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J. Agric. Food Chem. 2006, 54, 8956–8961.
126. González-Sarrías, A., Espín, J. C., Tomás-Barberán, F. A., García-Conesa, M. T., Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. Mol. Nutr. Food Res. 2009, 53, 686–698.
127. González-Sarrías, A., Núñez-Sánchez, M. A., García-Villalba, R., Tomás-Barberán, F. A. et al., Antiproliferative activity of the ellagic acid-derived gut microbiota isourolithin A and comparison with its urolithin A isomer: the role of cell metabolism. Eur. J. Nutr. 2015. doi: 10.1007/s00394-015-1131-7.
128. González-Sarrías, A., Tomé-Carneiro, J., Bellesia, A., Tomás-Barberán, F. A. et al., The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct. 2015, 6, 1460–1469.
129. Kasimsetty, S. G., Bialonska, D., Reddy, M. K., Ma, G. et al., Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J. Agric. Food Chem. 2010, 58, 2180–2187.
130. Ramírez de Molina, A., Vargas, T., Molina, S., Sánchez, J. et al., The ellagic acid derivative 4,4′-di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16. J. Pharmacol. Exp. Ther. 2015, 353, 433–444.
131. Sharma, M., Li, L., Celver, J., Killian, C. et al., Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling. J. Agric. Food Chem. 2010, 58, 3965–3969.
132. González-Sarrías, A., Miguel, V., Merino, G., Lucas, R. et al., The gut microbiota ellagic acid-derived metabolite urolithin A, and its sulfate conjugate, are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP). J. Agric. Food Chem. 2013, 61, 4352–4359.
133. Kasimsetty, S. G., Bialonska, D., Reddy, M. K., Thornton, C. et al., Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rvl prostate cancer cells. J. Agric. Food Chem. 2009, 57, 10636–10644.
134. Stolarczyk, M., Piwowarski, J. P., Granica, S., Stefanska, J. et al., Extract from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion. Phytother. Res. 2013, 27, 1842–1848.
135. Sánchez-González, C., Ciudad, C. J., Noé, V., Izquierdo-Pulido, M., Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells. Food Funct. 2014, 5, 2922–2930.
136. Vicinanza, R., Zhang, Y., Henning, S. M., Heber, D., Pomegranate juice metabolites, ellagic acid and urolithin A, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. Evid. Based Complement. Altern. Med. 2013, 2013, 247504
137. Kallio, T., Kallio, J., Jaakkola, M., Maki, M. et al., Urolithins display both antioxidant and pro-oxidant activities depending on assay system and conditions. J. Agric. Food Chem. 2013, 61, 10720–10729.
138. Adams, L. S., Zhang, Y., Seeram, N. P., Heber, D. et al., Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev. Res. (Phila.) 2010, 3, 108–113.
139. Cozza, G., Gianoncelli, A., Bonvini, P., Zorzi, E. et al., Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors. ChemMedChem. 2011, 6, 2273–2286.
140. Kiss, A. K., Granica, S., Stolarczyk, M., Melzig, M. F., Epigenetic modulation of mechanisms involved in inflammation: influence of selected polyphenolic substances on histone acetylation state. Food Chem. 2012, 131, 1015–1020.
141. Piwowarski, J. P., Kiss, A. K., Granica, S., Moeslinger, T., Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages. Mol. Nutr. Food Res. 2015, 59, 2168–2177.
142. Nealmongkol, P., Tangdenpaisal, K., Sitthimonchai, S., Ruchirawat, S., et al., Cu(I)-mediated lactone formation in subcritical water: a benign synthesis of benzopyranones and urolithins A-C. Tetrahedron. 2013, 69, 9277–9283.
143. Shirataki, Y., Toda, S., Antioxidative effects of dibenzo-α-pyrones in fruits of Trapa natans on lipid peroxidation. Nat. Med. 2001, 55, 247–250.
144. Ishimoto, H., Tai, A., Yoshimura, M., Amakura, Y. et al. Antioxidative properties of functional polyphenols and their metabolites assessed by an ORAC assay. Biosci. Biotechnol. Biochem. 2012, 76, 395–399.
145. Rozano, L., Zawawi, M. R. A., Ahmad, M. A., Jaganath, I. B., Comparative docking study of “dukung anak” phytonutrient compounds with anti-cholesterol properties. J. Teknol. 2015, 77, 37–43.
146. Dell'Agli, M., Galli, G. V., Corbett, Y., Taramelli, D. et al., Antiplasmodial activity of Punica granatum L. fruit rind. J. Ethnopharmacol. 2009, 125, 279–285.
147. Nagano, T., Ito, H., Okamoto, T., Inhibitory effect of ellagitannin metabolites on IgE-mediated allergic responses in RBL-2H3 cells. Biosci. Biotechnol. Biochem. 2012, 76, 2310–2312.